Dr. Piotr Wysocki
Claim this profileSamodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie Oddział Kliniczny Onkologii
Studies Breast Cancer
Studies Prostate Cancer
5 reported clinical trials
12 drugs studied
Area of expertise
1Breast Cancer
Stage III
BRCA positive
Stage IV
2Prostate Cancer
Stage IV
Clinical Trials Piotr Wysocki is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Fuzuloparib + AA-P
for Prostate Cancer
This trial is testing whether a combination of Fuzuloparib and AA-P is better for treating advanced prostate cancer. The treatment aims to kill cancer cells by preventing them from fixing their damaged DNA and by reducing hormone levels that help the cancer grow. The study includes patients with and without specific DNA repair deficiencies.
Recruiting1 award Phase 37 criteria
More about Piotr Wysocki
Clinical Trial Related1 year of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Piotr Wysocki has experience with
- MGC018
- MGA012
- Fuzuloparib
- Prednisone
- Abiraterone Acetate
- Fuzuloparib Placebo
Breakdown of trials Piotr Wysocki has run
Breast Cancer
Prostate Cancer
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Piotr Wysocki specialize in?
Piotr Wysocki focuses on Breast Cancer and Prostate Cancer. In particular, much of their work with Breast Cancer has involved Stage III patients, or patients who are BRCA positive.
Is Piotr Wysocki currently recruiting for clinical trials?
Yes, Piotr Wysocki is currently recruiting for 3 clinical trials in the USA. If you're interested in participating, you should apply.
Are there any treatments that Piotr Wysocki has studied deeply?
Yes, Piotr Wysocki has studied treatments such as MGC018, MGA012, Fuzuloparib.
What is the best way to schedule an appointment with Piotr Wysocki?
Apply for one of the trials that Piotr Wysocki is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.